1. Specific recommendations for prevention strategies often depend on the ischemic
stroke/transient ischemic attack subtype. Therefore, new in this guideline is a section …

1Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich,
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …

Background The effect of early as compared with later initiation of direct oral anticoagulants
(DOACs) in persons with atrial fibrillation who have had an acute ischemic stroke is unclear …

MicroRNAs (miRNAs) are small regulatory molecules post-transcriptionally suppressing
mRNA activity. Many miRNAs in various organisms have been cloned but many unknown …

Background Atrial fibrillation is frequently asymptomatic and thus underdetected but is
associated with stroke, heart failure, and death. Existing screening methods require …

Background: There are no evidence-based recommendations on the optimal time point to
initiate non–vitamin K antagonist oral anticoagulants (NOACs) after acute ischemic stroke in …

Atrial fibrillation (AF) is an important risk factor for ischemic stroke resulting in a fivefold
increased stroke risk and a twofold increased mortality. Our understanding of stroke …

Stroke is a major contributor to death and disability worldwide. Prior to modern therapy, post-
stroke mortality was approximately 10% in the acute period, with nearly one-half of the …

Biomarkers are objective indicators used to assess normal or pathological processes,
evaluate responses to treatment and predict outcomes. Many blood biomarkers already …

Background: The “1-3-6-12-day rule” for starting direct oral anticoagulants (DOACs) in
patients with nonvalvular atrial fibrillation after acute ischemic stroke or transient ischemic …